CLS highlights LITT + immunotherapy study for brain tumors
The study found improved survival in recurrent aggressive brain tumor patients treated with LITT and immune checkpoint inhibition.
See the latest news and media coverage for CLS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of laser ablation systems for cancer and neurosurgery
clinicallaser.seLast updated
In short: CLS expanded its neurosurgery market presence, reported positive clinical data for its laser ablation systems, and secured a 23 million SEK order.
The study found improved survival in recurrent aggressive brain tumor patients treated with LITT and immune checkpoint inhibition.
The annual report is available on the company's website and as an attached press release.
The meeting will be held in Lund, Sweden to vote on proposals including board elections, share capital reduction, and authorization for share issues.
CEO Dan Mogren and CFO Katarina Lundqvist hold the presentation from 13.00-13.45 today.
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its interim report for January - March 2026. Highlights of First...
Clinical Laserthermia Systems, CLS, has received an order with a total value of approximately 23 million kronor for its neurosurgical Prism business from...
Clinical Laserthermia Systems AB (CLS) today announced it has reached an agreement with its strategic partner on an alignment to accelerate the growth of the...
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its Year-end report for January - December 2025.Highlights of the Year-end...
Track CLS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CLS and other trending companies.